1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one | 328543-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one
• 英文别名: 2-[4-(Diethoxymethyl)phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
• CAS: 328543-05-1
• 化学式: C₂₁H₂₃N₃O₃
• 分子量: 365.432
• InChiKey: UALKJTNNHFZRMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one 在 盐酸 、 硫酸 、 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 5.0h， 生成 1-(4-hydroxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one
  参考文献：
  名称：

  Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors

  摘要：

  Novel tricyclic benzimidazole carboxamide poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been synthesized. Several compounds were found to be powerful chemopotentiators of temozolomide and topotecan in both A549 and LoVo cell lines. In vitro inhibition of PARP-1 was confirmed by direct measurement of NAD(+) depletion and ADPribose polymer formation caused by chemically induced DNA damage.

  DOI：

  10.1021/jm0255769
• 作为产物：
  描述：

  2-溴-3-硝基苯甲酸甲酯 在 palladium on activated charcoal 氢气 、 sodium hydrogensulfite 、 溶剂黄146 作用下， 以 N,N-二甲基乙酰胺 、 乙酸乙酯 为溶剂， 100.0 ℃ 、344.75 kPa 条件下， 反应 6.5h， 生成 1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one
  参考文献：
  名称：

  Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors

  摘要：

  Novel tricyclic benzimidazole carboxamide poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been synthesized. Several compounds were found to be powerful chemopotentiators of temozolomide and topotecan in both A549 and LoVo cell lines. In vitro inhibition of PARP-1 was confirmed by direct measurement of NAD(+) depletion and ADPribose polymer formation caused by chemically induced DNA damage.

  DOI：

  10.1021/jm0255769

文献信息

• Tricyclic inhibitors of poly(ADP-ribose) polymerases
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06548494B1

  公开（公告）日：2003-04-15

  Compounds of the formula shown below are poly(ADP-ribosyl)transferase inhibitors: Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.

  以下化学式显示的化合物是聚(ADP-核糖基)转移酶抑制剂：这些化合物在治疗癌症和改善中风、头部创伤和神经退行性疾病的疗效方面非常有用。
• Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye
  申请人：Zhang Jinzhong

  公开号：US20080305994A1

  公开（公告）日：2008-12-11

  A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression.
• US6548494B1
  申请人：——

  公开号：US6548494B1

  公开（公告）日：2003-04-15
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉ PERMETTANT DE TRAITER, RÉDUIRE, AMÉLIORER, ATTÉNUER, OU PRÉVENIR LA SÉCHERESSE OCULAIRE
  申请人：BAUSCH & LOMB

  公开号：WO2008154129A1

  公开（公告）日：2008-12-18

  [EN] A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an ophthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase ("PARP"). The composition can also include a modulator of pro-inflammatory gene expression.
  [FR] La présente invention concerne une composition permettant de traiter, réduire, améliorer, atténuer, ou prévenir un état de sécheresse oculaire ou un trouble ophtalmologique d'origine inflammatoire qui comprend un inhibiteur de l'activité de poly(ADP-ribose)-polymérase ('PARP'). La composition peut également inclure un modulateur de l'expression de gène pro-inflammatoire.